

Invitation



Meet the CTGCT - technologies in cell and gene therapy

Organised by the National Institute of Chemistry within the frame of the CTGCT initiative, EU Horizon, "Teaming for Excellence"

8th November, 2022 at 13.00 CET as an online conference

With the symposium we will address:

The core of the CTGCT initiative is collaboration between excellent research institutions and knowledge transfer to Slovenia to advance the translation of biomedical research on gene and cell therapies. The CTGCT environment, with its infrastructure and quality content, will create an environment that will adequately accept knowledge from abroad and develop it in the future in line with the needs of the Slovenian biomedical ecosystem. At this event, we will learn about the good practices of our partners, and the work of Slovenian researchers and clinicians.

Host institution:



The National Institute of Chemistry will contribute to the Centre's cutting-edge expertise in the field of the development of therapeutics for cancer and genetic diseases in combination with synthetic biology.

Partners of Excellence:



UCL will represent a key international strategic alliance through several of its units (IoN, Biochem Eng, IIT, TRO). They will advise on the organisation of the Centre, support the transfer of therapies from laboratories to patients and the market, train Centre staff and connect with regulators, companies and clinics. Through their experience and contacts, they will support the translation of Slovenian knowledge to the clinic. The Centre will also host joint research projects.



UMC Utrecht, as the main hospital of the city of Utrecht, Netherlands, has just finished establishing a GMP facility at their site and therefore has access to the latest technology providers and experience in the establishment of such a facility. Their knowledge will be vital to setting up the GMP facility. UMC Utrecht is also developing innovative methods in CAR T-cells and will therefore set up a joint research project with CTGCT. The Center for Translational Immunology (CTI) of UMC Utrecht concentrates top expertise on immunological diseases and will contribute to the development and assessment of innovative CAR T-cell methodologies.



Charité, one of the largest university hospitals in Europe and will enhance CTGCT's capabilities for refined transfer of research results to the first-in-human clinical practice and further accessibility of the ATMP as a treatment option for patients. It will provide access to Slovenia's patient organisations and to the research talents in the region. Furthermore, the Berlin Centre for Advanced Therapies (BeCAT) holds manufacturing authorisation for several GMP facilities that meet the highest quality and ethical standards.



TU Dresden will provide expertise, technology and equipment for gene editing and regeneration towards new therapies such as neurodegenerative and haematological diseases to boost CTGCT's clinical translation of research results and scientific efficiency.

The Programme and the Speakers



The Programme

Each speaker will have a 15 minutes presentation followed by 5 minutes for Q&A.
The whole event will be run in English language.

Institution	Speaker	Topic	Estimated time slot
NIC	Prof Mojca Benčina	Welcome word	13.00 – 13.10 CET (12.00 UK)
University Children's Hospital Ljubljana	Assoc Prof Damjan Osredkar, PhD, MD	In search of a treatment for a rare genetic disease, CTNNB1 syndrome	(20min) 13.10 – 13.30
NIC	Duško Lainšček, PhD	Enhanced Gene Editing by Coiled-coil Recruitment of an Exonuclease to CRISPR/Cas	(20min) 13.30 – 13.50
UCL	Pamela Tranter, PhD or Jane Kinghorn, PhD	The translational pathway through to commercialisation and education activities through UCL Therapeutic Innovation network	(20min) 13.50 – 14.10 (12.50 – 13.10 UK)
UCL	To be announced	The current aims and visions of neuro and oncology C>	(20min) 14.10 – 14.30 (13.10 – 13.30 UK)
			10min break/buffer
UMC Utrecht ICAT	Prof Colin de Haar	Harmonization and internationalization of Advanced Therapy Medical Products (ATMPs)	(20min) 14.40 – 15.00
Charité	Prof Petra Reinke	Current Scientific Challenges associated to Cell Therapies	(20min) 15.00 – 15.20
TU Dresden	Prof Michael Sieweke	Macrophage cell therapy	(20min) 15.20 – 15.40
UMC Utrecht ICAT	Prof Zsolt Sebestyén	$\gamma\delta$ T cells and T cells engineered to express a defined $\gamma\delta$ TCR (TEGs) in hematological and solid malignancies	(20min) 15.40 – 16.00
			10min break/buffer
NIC	Prof Jernej Ule	How the study of protein-RNA condensates in ALS opens new therapeutic opportunities	(20min) 16.10 – 16.30
TU Dresden	Prof Frank Buchholz	SaxoCell and the Dresden Genome Engineering Toolbox	(20min) 16.30 – 16.50
Charité	Dr Dimitrios Laurin Wagner / Jonas Kath	Future in Gene Editing	(20min) 16.50 – 17.10